Search details
1.
A randomized, placebo-controlled phase 2 study of paclitaxel in combination with reparixin compared to paclitaxel alone as front-line therapy for metastatic triple-negative breast cancer (fRida).
Breast Cancer Res Treat
; 190(2): 265-275, 2021 Nov.
Article
in English
| MEDLINE | ID: mdl-34476645
2.
Correction to: A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Breast Cancer Res
; 22(1): 52, 2020 05 20.
Article
in English
| MEDLINE | ID: mdl-32434589
3.
A window-of-opportunity trial of the CXCR1/2 inhibitor reparixin in operable HER-2-negative breast cancer.
Breast Cancer Res
; 22(1): 4, 2020 01 10.
Article
in English
| MEDLINE | ID: mdl-31924241
Results
1 -
3
de 3
1
Next >
>>